As malignant/refractory tumors have been one of the major public health issues that threaten the health of the Chinese population, the attention of "Precision Diagnosis and Treatment" has gradually increased from policy setting to industry need, which focuses more on advanced diagnosis technology with tumors treatment, drug development and clinical transformation. With the use of personalized treatment plan, to promote the implement of  P4 medicine that are abbreviated with Participatory, Predictive, Preventive and Personalized

• How to further promote the development and transformation of precision targeting/immunotherapy under the guidance of genetic testing/ CDx / biomarkers ?

• How to promote the implement of CDx model and LDT Compliance?

• How to further enhance Tumor Screening Technology, such as Liquid Biopsy?

• How to more accurately develop and implement tumor typing/prognostic test such as HRD, MRD and MSI, etc?

• How to dig the value of biomarkers in diagnosis, drug development and medication?

Facing the newest implement of Regulation on the Supervision and Administration of Medical Devices and incumbent  of , P4 China 2021 (5th International Convention on Precision Oncology-Detection and Personalized Medicine) will take place on Aug 20-21, 2021 in Beijing China. It will Focusing on the Current Hotspots and New Applications, especially focusing on the latest Regulations, new Technology and Products in the field of  Precision Oncology Detection, Oncology Drug Development and Personalized Medicine.